Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension safety and tolerability study of deferitazole (SSP-004184AQ/SPD602) in transfusional iron overload
2011-006322-25Phase 2Terminated
- Sponsor
- Takeda
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of deferitazole in hemochromatosis (HH), iron overload and Iron overload secondary to bone marrow failure syndromes (SIO), sponsored by Takeda. Primary endpoint: Primary as per objectives. Started Aug 2012; status: terminated.
02
Drugs
deferitazole
03
Conditions
hemochromatosis (HH)iron overloadIron overload secondary to bone marrow failure syndromes (SIO)
Beyond the preview
Go deeper on 2011-006322-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006322-25.